Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) announced that on November 4, 2025 it granted 77,650 restricted stock units (RSUs) to 23 new employees under its 2017 Inducement Equity Incentive Plan pursuant to NASDAQ Rule 5635(c)(4).
The RSUs vest 25% on the one-year anniversary of each recipient’s vesting commencement date and the remaining 75% in twelve equal quarterly installments thereafter, subject to continued employment. The awards are governed by the 2017 Inducement Equity Incentive Plan and individual RSU agreements.
Esperion is a commercial-stage biopharmaceutical company commercializing FDA-approved oral, once-daily non-statin medicines for patients with elevated LDL-C and references the nearly 14,000-patient CLEAR Cardiovascular Outcomes Trial.
Esperion (NASDAQ: ESPR) ha annunciato che il 4 novembre 2025 ha concesso 77.650 unità azionarie soggette a restrizioni (RSU) a 23 nuovi dipendenti nell'ambito del suo 2017 Inducement Equity Incentive Plan ai sensi della NASDAQ Rule 5635(c)(4).
Le RSU maturano il 25% al primo anniversario della data di inizio del vesting per ciascun beneficiario e il restante 75% in dodici rate trimestrali uguali successive, soggette al continuato impiego. I premi sono disciplinati dal 2017 Inducement Equity Incentive Plan e dai singoli accordi RSU.
Esperion è una società biofarmaceutica in fase commerciale che commercializza medicinali orali una volta al giorno, non statinici, approvati dalla FDA per pazienti con LDL-C elevato e fa riferimento al quasi 14.000-paziente CLEAR Cardiovascular Outcomes Trial.
Esperion (NASDAQ: ESPR) anunció que el 4 de noviembre de 2025 otorgó 77,650 unidades de acciones restringidas (RSU) a 23 nuevos empleados bajo su Plan de Incentivo de Acciones por Inducción de 2017, conforme a la Regla NASDAQ 5635(c)(4).
Las RSU se adquieren en un 25% al primer aniversario de la fecha de inicio de la adquisición y el 75% restante en doce cuotas trimestrales iguales a partir de entonces, sujeto a la continuidad del empleo. Los premios están regidos por el Plan de Incentivo de 2017 y por los acuerdos individuales de RSU.
Esperion es una empresa biotecnológica en fase comercial que comercializa medicamentos orales, de una vez al día, no statinas, aprobados por la FDA para pacientes con LDL-C elevado y hace referencia al casi ensayo de resultados cardiovasculares CLEAR con casi 14,000 pacientes.
Esperion (NASDAQ: ESPR)은 2025년 11월 4일에 NASDAQ Rule 5635(c)(4)에 따라 2017 Inducement Equity Incentive Plan에 따라 77,650개의 제한 주식 단위(RSU)를 23명의 신규 직원에게 부여했다고 발표했습니다.
RSU는 각 수혜자의 vesting 시작일로부터 1주년 시점에 25%가 vesting되고 이후 12분기 동안 매분기 동일한 75%가 vesting되며, 고용이 계속되어야 합니다. 이 상은 2017 Inducement Equity Incentive Plan 및 개별 RSU 계약에 의해 규율됩니다.
Esperion은 고혈 LDL-C를 가진 환자를 대상으로 FDA가 승인한 하루에 한 번 복용하는 비스타틴 계열의 경구 의약품을 상용화하는 상용 단계의 생물의약 회사이며, 거의 14,000명 환자 규모의 CLEAR Cardiovascular Outcomes Trial을 언급합니다.
Esperion (NASDAQ: ESPR) a annoncé que le 4 novembre 2025 elle a accordé 77 650 unités d’actions restreintes (RSU) à 23 nouveaux employés dans le cadre de son Plan d’Incitation en Actions d’Induction de 2017, conformément à la règle NASDAQ 5635(c)(4).
Les RSU se vestront à 25 % à l’occasion du premier anniversaire de la date de début de la vesting de chaque bénéficiaire et les 75 % restants seront versés en douze versements trimestriels égaux par la suite, sous réserve d’un maintien d’emploi. Les attributions sont régies par le Plan d’Incitation en Actions d’Induction de 2017 et par les accords RSU individuels.
Esperion est une société biopharmaceutique en phase commerciale qui commercialise des médicaments oraux une fois par jour, non statines, approuvés par la FDA pour les patients présentant un LDL-C élevé et fait référence à l’éprouvé CLEAR Cardiovascular Outcomes Trial d’environ 14 000 patients.
Esperion (NASDAQ: ESPR) kündigte an, dass am 4. November 2025 77.650 RSUs (Restricted Stock Units) an 23 neue Mitarbeiter im Rahmen des 2017 Inducement Equity Incentive Plans gemäß NASDAQ Regel 5635(c)(4) gewährt wurden.
Die RSUs vesten zu 25% am ersten Jahrestag des Vesting-Beginns jedes Empfängers und die restlichen 75% in zwölf gleichen vierteljährlichen Raten danach, vorbehaltlich einer fortbestehenden Anstellung. Die Zuwendungen unterliegen dem 2017 Inducement Equity Incentive Plan und den jeweiligen RSU-Vereinbarungen.
Esperion ist ein kommerziell orientiertes Biopharmaunternehmen, das FDA-audited orale, einmal täglich einzunehmende Nicht-Statin-Medikamente für Patienten mit erhöhtem LDL-C kommerzialisiert und verweist auf die nahezu 14.000-Patienten CLEAR Cardiovascular Outcomes Trial.
Esperion (NASDAQ: ESPR) أعلنت أنه في 4 نوفمبر 2025 منحت 77,650 وحدة أسهم مقيدة (RSUs) لـ 23 موظفًا جديدًا بموجب خطة حوافز الأسهم للعام 2017 وفقًا لقاعدة NASDAQ 5635(c)(4).
تستحق RSUs بنسبة 25% في الذكرى السنوية الأولى لبداية الاستحقاق لكل مستلم وتستحق النسبة المتبقية البالغة 75% على دفعات ربع سنوية متساوية خلال الاثني عشر شهرًا التالية، رهناً باستمرار التوظيف. تخضع الجوائز لهذه الخطة وللعقود الفردية لـ RSU.
Esperion هي شركة أدوية حيوية تجارية تسوّق أدوية فموية يومية غير ستاتينية معتمدة من إدارة الغذاء والدواء الأمريكية لمرضى elevation LDL-C وتشير إلى تجربة النتائج القلبية الوعائية CLEAR التي تضم قرابة 14,000 مريض.
- None.
- None.
ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Each RSU will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient’s vesting commencement date and will vest and become exercisable as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following such anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates. The RSUs are subject to the terms and conditions of Esperion’s 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
What did Esperion (ESPR) announce on November 4, 2025 about employee equity?
How do the RSU vesting terms for ESPR inducement grants work?
Under which plan were Esperion's November 2025 inducement RSUs awarded?
Does the November 2025 RSU announcement state the impact on ESPR share count or dilution?
What product and trial does Esperion highlight in the announcement?
Who can investors contact for more information about the ESPR inducement grants?
